GlassScriptPhysician profile
Amsel M Siore
NPI 1013097971
$9,572.66
in general payments reported to CMS, 2019-2025
40 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $2,779 · 2021: $868 · 2022: $1,209 · 2023: $1,806 · 2024: $1,093 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,219 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.10 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,638.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,399.45 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.77 | 2019-2024 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $404.30 | 2021-2025 | |
| Amgen INC. | $297.61 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $254.64 | 2020-2025 | Dupixent |
| Inspire Medical Systems, INC. | $244.09 | 2023-2025 | Inspire |
| Grifols USA, LLC | $242.52 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $216.12 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $172.68 | 2020-2023 | Acthar |
| Harmony Biosciences LLC | $164.19 | 2022-2025 | Wakix |
| Baxter Healthcare | $132.09 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $126.98 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $109.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.03 | 2020-2025 | Glassia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.41 | 2021-2022 | |
| United Therapeutics Corporation | $84.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Pfizer INC. | $77.59 | 2020-2022 | |
| Insmed, INC. | $68.78 | 2022-2025 | Arikayce, Brinsupri |
| Resmed Corp | $60.94 | 2023-2024 | |
| Invivyd INC | $58.83 | 2025 | Pemgarda |
| Abbvie INC. | $57.02 | 2023 | Avycaz, Teflaro |
| Sunovion Pharmaceuticals INC. | $56.56 | 2019 | |
| Verona Pharma, INC. | $54.09 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $51.01 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $39.28 | 2022-2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $37.18 | 2021-2023 | |
| Portola Pharmaceuticals, LLC | $34.76 | 2019 | |
| Edwards Lifesciences Corporation | $28.28 | 2025 | Sapien 3 Ultra Resilia |
| Teva Pharmaceuticals USA, INC. | $25.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.28 | 2025 | Orencia |
| Paratek Pharmaceuticals, INC. | $22.34 | 2024 | Nuzyra |
| Csl Behring | $21.15 | 2024 | Hizentra |
| Octapharma USA, INC. | $20.55 | 2025 | Octagam Immune Globulin (Human) |
| Electromed, INC. | $19.82 | 2022 | |
| Pulmonx Corporation | $19.57 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Axsome Therapeutics, INC. | $18.61 | 2025 | Sunosi |
| Gilead Sciences, INC. | $16.62 | 2022 | |
| La Jolla Pharmaceutical Company | $13.99 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amsel Siore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.